Better data in real time
eCOAs and digital outcome measures delivered at industry-leading speed and quality to enhance your trial findings and fuel medical breakthroughs.
eCOA+ is part of Medable's unified data collection platform, which includes eConsent, telehealth, and sensors, with standardized integrations into your existing clinical ecosystem.
Medable eCOA+
Faster study build time
Pre-built and validated instruments
Available languages
Take eCOA off the critical path
Rapidly deploy quality studies and take eCOA off the critical path of study start-up with a reusable instrument library of 380+ standardized workflows and AI-enabled, purpose-built technology so you can work on what matters most, advancing patient care.
Unlock insights with real-time data capture
Capture objective and subjective participant data in a standardized and compliant manner. Medable’s eCOA+ combines eClinROs, ePROs, ePerfOs, eObsROs, and digital measures, so you can uncover clinically meaningful insights in real-time.
Engage patients with a better experience
Medable’s eCOA+ improves inclusivity and accessibility, meeting the needs of patients in any geographic location and across diverse therapeutic areas, reducing burden and increasing retention.
The Medable difference
Reusable eCOA+ Library
Our library of 380+ reusable, pre-validated instruments, assessments and diaries ensure a standardized, consistent method of data collection that drives real-time decision making.
BYOD and provisioned devices
Accessible across web and/or mobile, provisioned devices or BYOD, unlocking patient populations that were previously out of reach while increasing patients' optionality.
Cross-platform TeleVisit
One seamless platform experience allows site and patient users to better engage and participate in a comfortable environment, reducing burden and increasing compliance.
Digital measures
Standardized integrations for sensors capturing digital physiological measures provide value across a variety of therapeutic areas including Oncology, Immunology, Cardiovascular, and more.
User friendy Platform
Consumer-grade UX, complete with notifications, reports, and submission-ready data, is vetted by our Patient Caregiver Network (PCN) and clinicians, ensuring accessibility.
24/7 Customer Support
Global customer care support throughout your trial for sites, patients and study teams. Our team ensure the best user experience to enable seamless technology adoption, protocol compliance, and overall user satisfaction.
Globally Compliant
Available in 60+ countries and 120+ languages, Medable’s platform is FDA, CFR21 Part 11, HIPAA, and GDPR compliant.
Powered by AI
By harnessing intelligent automation, we can reduce delivery timelines by up to 50%, enabling an accelerated study start up to quickly capture novel endpoints.
A top-10 American pharmaceutical company came to Medable looking to conduct an extensive weight management master protocol clinical trial with multiple sub-studies across 70+ research sites. The client was concerned about the participant experience, as the trial required participants to enroll through the master protocol before enrolling into a sub-study. Additionally, they wanted to reuse and scale the solution for future trials without compromising the site and patient experience. Learn how Medable was able to accomplish this and more.
eCOA+ Streamlined Evidence Generation
Frequently asked questions
eCOA stands for electronic clinical outcome assessment and uses electronic devices like tablets, desktop computers, and phones to collect data from trial participants. Participants complete diaries, questionnaires, or other prompts to communicate how they are feeling or functioning during the course of a clinical trial. eCOAs are part of the decentralized clinical trial (DCT) methodology and are essential to understanding whether a drug is reducing symptoms and improving patients’ quality of life.
Medable’s eCOA offering is part of our broader evidence generation offering: Patient-First Data Collection. Medable’s tools allow teams to build eCOA instruments (both validated instruments and eDiaries) that meet industry standards. Data collected from this system can be used for primary endpoints in pivotal studies. Study teams can store instruments, including translations, in a library for rapid deployment in future studies. Dashboards keep teams informed of all startup activities along the way. Teams may also access their library of prebuilt, validated instruments to improve study startup.
Yes. Medable's platform is multimodal, meaning patients can access our interface through the Patient app or a web browser. A BYOD model allows patients to use their own smartphone or other device for data capture during a site visit or remotely. Participants using devices they are already familiar with may lead to better compliance and ultimately, a better clinical trial experience. However, since some participants may be hesitant to download an app on their own device, or may not own a device that meets the requirements, it’s important to anticipate a percentage of provisioned devices, even in trials adopting a BYOD strategy.
The latest in eCOA
Medable platform delivers >90% eCOA adherence and scalability
A top-10 American pharmaceutical company came to Medable looking to conduct an extensive weight management master protocol clinical trial with multiple sub-studies across 70+ research sites. The client was concerned about the participant experience, as the trial required participants to enroll through the master protocol before enrolling into a sub-study. Additionally, they wanted to reuse and scale the solution for future trials without compromising the site and patient experience.
Learn how Medable was able to accomplish this and more.
Evidence generation evolved
The pharmaceutical industry faces a daunting challenge: it takes an average of 12 years and $3 billion to bring a new drug to patients, with the FDA approving an average of 50 new therapies yearly.
This pace is inadequate to address humanity's needs and our own future goal of helping the industry produce ten times the number of treatments it does today.
A significant bottleneck is the lengthy clinical trial process, where Phase 3 studies alone can span three years or more. However, a critical factor compounding these timelines is the difficulty in recruiting sufficient patients for these crucial studies, often adding up to 2 years to the already protracted journey.
Use case: How a top-10 pharma digitized and standardized participant pain body maps
A top-10 pharmaceutical company was looking to standardize the conduct of their diabetic polyneuropathy trials for future use.
Specifically, the client was looking to digitize their paper “body map” forms. These are used by participants to indicate the severity of pain on their bodies.
Traditionally administered on paper, body map assessments had been a source of potential inefficiencies and errors.
The client’s goal was to co-create and own their body maps, while simplifying and streamlining the process for future trials.